Looking beyond the WRIB Decennial Index of the White Papers in Bioanalysis

References

• 1. Savoie N, Booth BP, Bradley T et al.The 2nd Calibration and Validation Group Workshop on recent issues in Good Laboratory Practice bioanalysis. Bioanalysis 1(1), 19–30 (2009).
  CASGoogle Scholar
• 2. Savoie N, Garofolo F, van Amsterdam P et al.2009 White Paper on recent issues in regulated bioanalysis from the 3rd Calibration and Validation Group Workshop. Bioanalysis 2(1), 53–68 (2010).
  CASGoogle Scholar
• 3. Savoie N, Garofolo F, van Amsterdam P et al.2010 White Paper on recent issues in regulated bioanalysis and global harmonization of bioanalytical guidance. Bioanalysis 2(12), 1945–1960 (2010).
  CASGoogle Scholar
• 4. Garofolo F, Rocci M, Dumont I et al.2011 White Paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis 3(18), 2081–2096 (2011).
  CASGoogle Scholar
• 5. DeSilva B, Garofolo F, Rocci M et al.2012 White Paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis 4(18), 2213–2226 (2012).
  CASGoogle Scholar
• 6. Stevenson L, Rocci M, Garofolo F et al.2013 White Paper on recent issues in bioanalysis: “hybrid” – the best of LBA & LC/MS. Bioanalysis 5(23), 2903–2918 (2013).
  CASGoogle Scholar
• 7. Fluhler E, Hayes R, Garofolo F et al.2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1 – small molecules by LCMS). Bioanalysis 6(22), 3039–3049 (2014).
  CASGoogle Scholar
• 8. Dufield D, Neubert H, Garofolo F et al.2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 – hybrid LBA/LCMS, ELN & regulatory agencies’ input). Bioanalysis 6(23), 3237–3249 (2014).
  CASGoogle Scholar
• 9. Stevenson L, Amaravadi L, Myler H et al.2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 – LBA and immunogenicity). Bioanalysis 6(24), 3355–3368 (2014).
  CASGoogle Scholar
• 10. Welink J, Fluhler E, Hughes N et al.2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1 – small molecules by LCMS). Bioanalysis 7(22), 2913–2925 (2015).
  CASGoogle Scholar
• 11. Ackermann B, Neubert H, Hughes N et al.2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 – hybrid LBA/LCMS and input from regulatory agencies). Bioanalysis 7(23), 3019–3034 (2015).
  CASGoogle Scholar
• 12. Amaravadi L, Song A, Myler H et al.2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3 – LBA, biomarkers and immunogenicity). Bioanalysis 7(24), 3107–3124 (2015).
  CASGoogle Scholar
• 13. Yang E, Welink J, Cape S et al.2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (Part 1 – small molecules, peptides and small molecule biomarkers by LCMS). Bioanalysis 8(22), 2363–2378 (2016).
  CASGoogle Scholar
• 14. Song A, Lee A, Garofolo F et al.2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 – hybrid LBA/LCMS and input from regulatory agencies). Bioanalysis 8(23), 2457–2474 (2016).
  CASGoogle Scholar
• 15. Richards S, Amaravadi L, Pillutla R et al.2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 – LBA, biomarkers and immunogenicity). Bioanalysis 8(23), 2475–2496 (2016).
  CASGoogle Scholar
• 16. Welink J, Yang E, Hughes N et al.2017 White Paper on recent issues in bioanalysis: aren’t BMV guidance/guidelines ‘scientific’? (Part 1 – LCMS: small molecules, peptides and small molecule biomarkers). Bioanalysis 9(22), 1807–1825 (2017).
  CASGoogle Scholar
• 17. Neubert H, Song A, Lee A et al.2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies’ inputs). Bioanalysis 9(23), 1895–1912 (2017).
  CASGoogle Scholar
• 18. Gupta S, Richards S, Amaravadi L et al.2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 – LBA: immunogenicity, biomarkers and PK assays). Bioanalysis 9(24), 1967–1996 (2017).
  CASGoogle Scholar
• 19. Welink J, Xu Y, Yang E et al. 2018 White Paper on Recent Issues in Bioanalysis: ‘a global bioanalytical community perspective on last decade of incurred samples reanalysis (ISR)’ (Part 1 – small molecule regulated bioanalysis, small molecule biomarkers, peptides & oligonucleotide bioanalysis). Bioanalysis 10(22), 1781–1801 (2018).
  CASGoogle Scholar
• 20. Neubert H, Olah T, Lee A et al.2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies’ inputs on bioanalysis, biomarkers and immunogenicity). Bioanalysis 10(23), 1897–1917 (2018).
  CASGoogle Scholar
• 21. Stevenson L, Richards S, Pillutla R et al.2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 – LBA/cell-based assays: immunogenicity, biomarkers and PK assays). Bioanalysis 10(24), 1973–2001 (2018).
  CASGoogle Scholar
• 22. Future Science. Most read Bioanalysis articles. www.future-science.com/journals/bio/mostread
  Google Scholar
• 23. Garofolo W & Savoie N. The Decennial Index of the White Papers in Bioanalysis: ‘a decade of recommendations (2007–2016)’. Bioanalysis 9(21), 1681–1704 (2017).
  Google Scholar
• 24. Bioanalysis Zone: The decennial index of White Papers in Bioanalysis: an interview with Natasha Savoie. www.bioanalysis-zone.com/2018/06/22/decennial-index-white-papers-bioanalysis-interview-natasha-savoie/
  Google Scholar
• 25. Bioanalysis. www.future-science.com/journal/bio
  Google Scholar
• 26. WRIB: Submit Your Questions to Regulators. www.wrib.org/questions-to-regulators.php
  Google Scholar